Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is X-linked hereditary disease from the group of lysosomal storage disease. Its prevalence is 3–7 cases per 1 million live-born boys. MPS II occurs due to the deficiency of iduronate-2-sulfatase enzyme because of pathological changes in the structure of the IDS gene. Enzyme deficiency leads to the accumulation of glycosaminoglycans (GAGs), dermatan sulfate and heparan sulfate, in lysosomes. This leads to the damage of various organs and systems in the body with further development of clinical picture of the disease: coarse face, recurrent infections of upper respiratory tract, hearing loss up to deafness, cardiovascular and respiratory systems pathologies, hepatosplenomegaly, musculoskeletal system abnormalities, low growth, central nervous system damage. Enzyme replacement therapy with idursulfase, that was introduced in clinical practice 15 years ago, has significantly changed the quality of life of these patients. Idursulfase is purified form of natural lysosomal enzyme iduronate-2-sulfatase obtained via human cell line. Exogenous enzyme entry promotes GAGs catabolism in cells. This article provides outcomes analysis of foreign and Russian studies on the efficacy and safety of this medication, and its effect on MPS II patients survivability.

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–254. doi: 10.1001/jama.281.3.249

2. Tuschl K, Gal A, Paschke E, et al. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatric Neurology. 2005;32(4):270–272. doi: 10.1016/j.pediatrneurol.2004.10.009

3. Semyachkina AN, Voskoboeva EY, Zakharova EY, et al. Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl. BMC Med Genet. 2019;20(1):66. doi: 10.1186/s12881-019-0807-x

4. Hunter C. A Rare Disease in Two Brothers. Proc R Soc Med. 1917;10(Sect Study Dis Child):104–116.

5. Froissart R, Moreira da Silva I, Guffon N, et al. Muco polysaccharidosis type II — genotype/phenotype aspects. Acta Paediatr Suppl. 2002;91(439):82–87. doi: 10.1111/j.1651-2227.2002.tb03116.x

6. Rigoldi M, Verrecchia E, Manna R, Mascia MT. Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses. Ital J Pediatr. 2018;44(Suppl 2):132. doi: 10.1186/s13052-018-0551-4

7. Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms. Mol Genet Metab. 2017;122S: 1–7. doi: 10.1016/j.ymgme.2017.08.009

8. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3): 267–277. doi: 10.1007/s00431-007-0635-4

9. Jones SA, Almássy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II‐a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2008;32(4):534–543. doi: 10.1007/s10545-009-1119-7

10. de Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem. 1992;38(6):803–807.

11. Kresse H, Figura K, Klein U, et al. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods in Enzymology. 1982;83:559–572. doi: 10.1016/0076-6879(82)83052-8

12. Martin R, Beck M, Eng C, et al. Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome). Pediatrics. 2008; 121(2):e377–e386. doi: 10.1542/peds.2007-1350

13. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Valle DL, Antonarakis S, et al., eds. New York, NY: McGraw‐Hill; 2001. pp. 3421–3452.

14. Muenzer J, Jones SA, Tylki-Szymańska A, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017;12(1):82. doi: 10.1186/s13023-017-0635-z

15. Coman DJ, Hayes IM, Collins V, et al. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr. 2008;152(5):723–727. doi: 10.1016/j.jpeds.2007.10.015

16. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473. doi: 10.1097/01.gim.0000232477.37660.fb

17. Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101. doi: 10.1097/GIM.0b013e3181fea459

18. Giugliani R, Hwu WL, Tylki-Szymanska A, et al. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med. 2014;16(6):435–441. doi: 10.1038/gim.2013.162

19. Burton BK, Whiteman DA. Incidence and timing of infusionrelated reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103(2):113–120. doi: 10.1016/j.ymgme.2011.02.018

20. Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome — an expert panel consensus. Eur J Pediatr. 2012;171(1):181–188. doi: 10.1007/s00431-011-1606-3

21. Lampe C, Bosserhoff AK, Burton BK, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis. 2014;37(5):823–829. doi: 10.1007/s10545-014-9686-7

22. Lampe C, Atherton A, Burton BK, et al. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age. JIMD Rep. 2014;14:99–113. doi: 10.1007/8904_2013_289

23. Tylki-Szymanska A, Giugliani R, Hwu WL. A clinical trial of idursulfase in Hunter syndrome patients 5 years old and younger [abstract]. J Inherit Metab Dis. 2008;31(Suppl 1):130.

24. Barbier AJ, Bielefeld B, Whiteman DAH, et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase. Mol Genet Metab. 2013;110(3):303–310. doi: 10.1016/j.ymgme.2013.08.002

25. Bradley L, Haddow H, Palomaki G. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review. Genet Med. 2017;19(11):1187–1201. doi: 10.1038/gim.2017.30

26. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007; 90(3):329–337. doi: 10.1016/j.ymgme.2006.09.001

27. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25. doi: 10.1016/j.ymgme.2009.08.00

28. da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2016; 2(2):CD008185. doi: 10.1002/14651858.CD008185.pub4

29. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. doi: 10.1186/1750-1172-6-72.

30. Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfasetreated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017;40(6):867–874. doi: 10.1007/s10545-017-0075-x

31. Broomfield A, Davison J, Roberts J, et al. Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England. Mol Genet Metab. 2020;129(2):98–105. doi: 10.1016/j.ymgme.2019.07.016

32. Pano A, Barbier AJ, Bielefeld B, et al. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2015;10:50. doi: 10.1186/s13023-015-0265-2

33. Baranov AA, Namazova-Baranova LS, Gevorkyan AK, et al. Experience of implementing new technology treatment of children with MPS in the Russian pediatric practice. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2011;8(5):6–12. (In Russ.)

34. Buchinskaya NV, Chikova IA, Isupova YeA, et al. Modern Approaches to Therapy for Children with Mucopolysaccharidosis. Voprosy sovremennoi pediatrii — Current Pediatrics. 2014;13(3):35–43. (In Russ).

35. Moiseev SV, Novikov PI, Fedorov KE, et al. Mucopolysaccharidosis type II (Hunter syndrome). Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2015;24(1):76–82. (In Russ).

36. Vakhlova IV, Bakhareva LI, Popova TV, et al. The experience of application of enzyme-substitute therapy in patients with Hunter syndrome. Disease Treatment and Prevention. 2014;(1):62–69. (In Russ).

37. Vashakmadze ND. Mul’tidistsiplinarnye printsipy vedeniya detei s mukopolisakharidozami v povyshenii effektivnosti ikh diagnostiki i lecheniya. [abstact of dissertation]. Ekaterinburg; 2019. 47 p. (In Russ).